gumarontinib + third-generation EGFR-TKI

Gumarontinib + third-generation EGFR-TKI is a combination therapy regimen being evaluated for the treatment of MET-amplified non-small cell lung cancer (NSCLC). This regimen pairs gumarontinib (SCC244), a highly selective, potent oral MET inhibitor, with one of several third-generation EGFR tyrosine kinase inhibitors (TKIs), including osimertinib, almonertinib, or furmonertinib. The combination is designed to overcome resistance in patients who have progressed on prior EGFR-TKI therapy due to MET amplification, a common bypass signaling mechanism. By simultaneously inhibiting the EGFR and MET pathways, the therapy aims to restore anti-tumor activity in advanced or metastatic NSCLC. The combination is being evaluated in a Phase 2 study sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Brand names

GlunhomeAmeileIvesa

Other names

osimertinib + almonertinib + furmonertinib-Cancer Institute and Hospital, Chinese Academy of Medical Sciences-non-small cell lung cancergumarontinib + osimertinibgumarontinib + almonertinibgumarontinib + furmonertinibSCC244 + 3rd-gen EGFR-TKI